| COOPERATION |
HARLOW, England, Nov. 21 /PRNewswire/ -- Argenta Discovery Ltd today announced that it has entered into a new fee for service research agreement with Aventis Pharmaceuticals Inc., Bridgewater, NJ, USA. Aventis and its worldwide affiliates will have the ability over a three year period to order research services that draw on Argenta's entire complement of chemical and biological research capabilities, spanning the drug discovery process from target to candidate, including: compound and library synthesis, medicinal chemistry, computer-aided drug design (CADD), biochemical screening, assay development, cellular screening and in vitro pharmacokinetics. Commenting on the agreement Dr Anthony Baxter, Argenta's CEO, said, "Aventis has been an important and valued partner for Argenta since the company was founded in August 2000. The new agreement is a reflection of Aventis' confidence in the value that Argenta has delivered and can deliver on collaborative projects. We are extremely pleased that our relationship continues." |
| UPDATE | 11.03 |
| COMPANY |
- Argenta Discovery - Aventis Pharma |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |